文献速递肿瘤 PET/CT

靶向人CD44的工程化单链抗体片段-可结晶片段融合蛋白的临床前评价

Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44.
PubMed 文献 · J Nucl Med · 2020-06-08

研究通过噬菌体展示技术制备抗人CD44单链抗体片段(scFv),并重组为二价scFv-Fc融合蛋白,用64Cu和89Zr标记后在CD44阳性三阴性乳腺癌MDA-MB-231荷瘤裸鼠中进行生物分布与PET/CT显像。结果显示二价scFv-Fc对天然CD44的亲和力较单价scFv提高近200倍,[89Zr]Zr-DFO-scFv-Fc-CD44在注射后5至7天肿瘤摄取最高,PET显像证实其肿瘤特异性优于对照scFv-Fc。

要点

  • 二价scFv-Fc-CD44对乳腺癌细胞天然CD44的亲和力较单价scFv提高近200倍。
  • [89Zr]Zr-DFO-scFv-Fc-CD44在注射后第5至7天肿瘤摄取与肿瘤/血比值最高。
  • 肿瘤摄取约56%注射剂量/克,作者认为值得对CD44阳性肿瘤患者开展临床研究。

核心结论

  • 研究开发出以纳摩尔级亲和力结合人CD44的scFv-Fc构建体,用64Cu或89Zr标记后在CD44阳性MDA-MB-231肿瘤中显示特异性摄取。
  • 高肿瘤摄取(约56%注射剂量/克)值得对[89Zr]Zr-DFO-scFv-Fc-CD44作为CD44阳性肿瘤患者通用PET显像剂开展临床研究。

研究设计与样本

  • 临床前研究:通过噬菌体展示技术以重组人CD44胞外域制备人scFv,并重组为基于人IgG1可结晶片段(Fc)的二价scFv-Fc-CD44。
  • 用64Cu和89Zr对scFv-Fc-CD44进行放射性标记,将纯化试剂注射入荷CD44阳性人肿瘤(MDA-MB-231三阴性乳腺癌)的裸鼠。
  • 注射[64Cu]Cu-NOTA-scFv-Fc-CD44或[89Zr]Zr-DFO-scFv-Fc-CD44后不同时间进行生物分布研究。
  • 注射[89Zr]Zr-DFO-scFv-Fc-CD44后第1天和第7天进行PET/CT显像,并与靶向血型糖蛋白A的scFv-Fc对照抗体构建体比较。

主要发现

  • scFv结合位点的表位定位显示人CD44胞外域内存在线性表位,能够阻断与天然透明质酸的结合。
  • 由单价scFv转换为二价scFv-Fc格式后,对人乳腺癌细胞天然CD44的结合亲和力提高近200倍。
  • 体内生物分布数据显示,[89Zr]Zr-DFO-scFv-Fc-CD44在第5至7天肿瘤摄取和肿瘤/血比值最高。
  • PET显像证实[89Zr]Zr-DFO-scFv-Fc-CD44与对照scFv-Fc相比具有优良的肿瘤特异性。

关键数值与推荐

  • 二价scFv-Fc-CD44对人乳腺癌细胞天然CD44的结合亲和力较单价scFv提高近200倍。
  • [89Zr]Zr-DFO-scFv-Fc-CD44肿瘤摄取约56%注射剂量/克。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glycoprotein CD44 and alternative splice variants are overexpressed in many cancers and cancer stem cells. Binding of hyaluronic acid to CD44 activates cell signaling pathways, inducing cell proliferation, cell survival, and invasion. As such, CD44 is regarded as an excellent target for cancer therapy when this interaction can be blocked. In this study, we developed a CD44-specific antibody fragment and evaluated it for imaging CD44-positive cancers using PET. Methods: A human single-chain fragment variable (scFv) was generated by phage display, using the extracellular domain of recombinant human CD44. The specificity and affinity of the scFv-CD44 were evaluated using recombinant and tumor cell-expressed CD44. Epitope mapping of the putative CD44 binding site was performed via overlapping peptide microarray. The scFv-CD44 was reformatted into a bivalent scFv-Fc-CD44, based on human IgG1-fragment crystallizable (Fc). The scFv-Fc-CD44 was radiolabeled with 64Cu and 89Zr. The purified reagents were injected into athymic nude mice bearing CD44-positive human tumors (MDA-MB-231, breast cancer, triple-negative). Biodistribution studies were performed at different times after injection of [64Cu]Cu-NOTA-scFv-Fc-CD44 or [89Zr]Zr-DFO-scFv-Fc-CD44. PET/CT imaging was conducted with [89Zr]Zr-DFO-scFv-Fc-CD44 on days 1 and 7 after injection and compared with a scFv-Fc control antibody construct targeting glycophorin A. Results: Epitope mapping of the scFv binding site revealed a linear epitope within the extracellular domain of human CD44, capable of blocking binding to native hyaluronic acid. Switching from a monovalent scFv to a bivalent scFv-Fc format improved its binding affinity toward native CD44 on human breast cancer cells by nearly 200-fold. In vivo biodistribution data showed the highest tumor uptake and tumor-to-blood ratios for [89Zr]Zr-DFO-scFv-Fc-CD44 between days 5 and 7. PET imaging confirmed excellent tumor specificity for [89Zr]Zr-DFO-scFv-Fc-CD44 when compared with the control scFv-Fc. Conclusion: We developed a CD44-specific scFv-Fc construct that binds with nanomolar affinity to human CD44. When radiolabeled with 64Cu or 89Zr, it demonstrated specific uptake in CD44-expressing MDA-MB-231 tumors. The high tumor uptake (∼56% injected dose/g) warrants clinical investigation of [89Zr]Zr-DFO-scFv-Fc-CD44 as a versatile PET imaging agent for patients with CD44-positive tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Diebolder P, Mpoy C, Scott J, et al. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44. J Nucl Med. 2020. PMID: 32513906. doi:10.2967/jnumed.120.249557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。